External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy

Shahrokh F. Shariat, Jochen Walz, Claus G. Roehrborn, Alexandre R. Zlotta, Paul Perrotte, Nazareno Suardi, Fred Saad, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: Biomarker signatures currently are used in several malignancies to guide clinical decision making. Recently, preoperative plasma levels of transforming growth factor-β1 (TGF-β1) and interleukin-6 soluble receptor (IL6-SR) have improved the accuracy of a clinical nomogram that predicted biochemical recurrence after radical prostatectomy. However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort. Patients and Methods: Preoperative plasma levels of TGF-β1 and IL6-SR were measured in 423 consecutive men who underwent radical prostatectomy and bilateral lymphadenectomy and were used, along with preoperative prostate-specific antigen levels, biopsy Gleason sum, and clinical stage to determine nomogram-derived probabilities of biochemical recurrence-free survival at 5 years after radical prostatectomy. The accuracy of predictions was quantified with the area under the curve (AUC) and calibration plots that graphically displayed the nomogram's performance characteristics. The statistical significance of the difference between the biomarker nomogram and a model designed on the basis of clinical variables alone was tested by using the Mantel-Haenszel statistic. Results: Biochemical recurrence-free survival at 5 years was 77.0% (95% CI, 72.0% to 82.0%). The biomarker-based nomogram was 87.9% accurate versus 71.1% for the nomogram designed on the basis of clinical variables alone (16.8% difference; P <.001). The performance characteristics of the biomarker-based nomogram were superior to those of the clinical nomogram. Conclusion: We confirm that plasma levels of TGF-β1 and IL6-SR considerably enhance the accuracy of the standard preoperative nomogram for the prediction of biochemical recurrence after radical prostatectomy. This model further refines our ability to identify patients at a high risk of biochemical recurrence after radical prostatectomy.

Original languageEnglish
Pages (from-to)1526-1531
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Nomograms
Prostatectomy
Biomarkers
Recurrence
Interleukin-6 Receptors
Transforming Growth Factors
Survival
Prostate-Specific Antigen
Lymph Node Excision
Calibration
Area Under Curve
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. / Shariat, Shahrokh F.; Walz, Jochen; Roehrborn, Claus G.; Zlotta, Alexandre R.; Perrotte, Paul; Suardi, Nazareno; Saad, Fred; Karakiewicz, Pierre I.

In: Journal of Clinical Oncology, Vol. 26, No. 9, 2008, p. 1526-1531.

Research output: Contribution to journalArticle

Shariat, Shahrokh F. ; Walz, Jochen ; Roehrborn, Claus G. ; Zlotta, Alexandre R. ; Perrotte, Paul ; Suardi, Nazareno ; Saad, Fred ; Karakiewicz, Pierre I. / External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 9. pp. 1526-1531.
@article{f5c0f8ff8cba4fc9bd0136a82b1db86f,
title = "External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy",
abstract = "Purpose: Biomarker signatures currently are used in several malignancies to guide clinical decision making. Recently, preoperative plasma levels of transforming growth factor-β1 (TGF-β1) and interleukin-6 soluble receptor (IL6-SR) have improved the accuracy of a clinical nomogram that predicted biochemical recurrence after radical prostatectomy. However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort. Patients and Methods: Preoperative plasma levels of TGF-β1 and IL6-SR were measured in 423 consecutive men who underwent radical prostatectomy and bilateral lymphadenectomy and were used, along with preoperative prostate-specific antigen levels, biopsy Gleason sum, and clinical stage to determine nomogram-derived probabilities of biochemical recurrence-free survival at 5 years after radical prostatectomy. The accuracy of predictions was quantified with the area under the curve (AUC) and calibration plots that graphically displayed the nomogram's performance characteristics. The statistical significance of the difference between the biomarker nomogram and a model designed on the basis of clinical variables alone was tested by using the Mantel-Haenszel statistic. Results: Biochemical recurrence-free survival at 5 years was 77.0{\%} (95{\%} CI, 72.0{\%} to 82.0{\%}). The biomarker-based nomogram was 87.9{\%} accurate versus 71.1{\%} for the nomogram designed on the basis of clinical variables alone (16.8{\%} difference; P <.001). The performance characteristics of the biomarker-based nomogram were superior to those of the clinical nomogram. Conclusion: We confirm that plasma levels of TGF-β1 and IL6-SR considerably enhance the accuracy of the standard preoperative nomogram for the prediction of biochemical recurrence after radical prostatectomy. This model further refines our ability to identify patients at a high risk of biochemical recurrence after radical prostatectomy.",
author = "Shariat, {Shahrokh F.} and Jochen Walz and Roehrborn, {Claus G.} and Zlotta, {Alexandre R.} and Paul Perrotte and Nazareno Suardi and Fred Saad and Karakiewicz, {Pierre I.}",
year = "2008",
doi = "10.1200/JCO.2007.12.4669",
language = "English",
volume = "26",
pages = "1526--1531",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy

AU - Shariat, Shahrokh F.

AU - Walz, Jochen

AU - Roehrborn, Claus G.

AU - Zlotta, Alexandre R.

AU - Perrotte, Paul

AU - Suardi, Nazareno

AU - Saad, Fred

AU - Karakiewicz, Pierre I.

PY - 2008

Y1 - 2008

N2 - Purpose: Biomarker signatures currently are used in several malignancies to guide clinical decision making. Recently, preoperative plasma levels of transforming growth factor-β1 (TGF-β1) and interleukin-6 soluble receptor (IL6-SR) have improved the accuracy of a clinical nomogram that predicted biochemical recurrence after radical prostatectomy. However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort. Patients and Methods: Preoperative plasma levels of TGF-β1 and IL6-SR were measured in 423 consecutive men who underwent radical prostatectomy and bilateral lymphadenectomy and were used, along with preoperative prostate-specific antigen levels, biopsy Gleason sum, and clinical stage to determine nomogram-derived probabilities of biochemical recurrence-free survival at 5 years after radical prostatectomy. The accuracy of predictions was quantified with the area under the curve (AUC) and calibration plots that graphically displayed the nomogram's performance characteristics. The statistical significance of the difference between the biomarker nomogram and a model designed on the basis of clinical variables alone was tested by using the Mantel-Haenszel statistic. Results: Biochemical recurrence-free survival at 5 years was 77.0% (95% CI, 72.0% to 82.0%). The biomarker-based nomogram was 87.9% accurate versus 71.1% for the nomogram designed on the basis of clinical variables alone (16.8% difference; P <.001). The performance characteristics of the biomarker-based nomogram were superior to those of the clinical nomogram. Conclusion: We confirm that plasma levels of TGF-β1 and IL6-SR considerably enhance the accuracy of the standard preoperative nomogram for the prediction of biochemical recurrence after radical prostatectomy. This model further refines our ability to identify patients at a high risk of biochemical recurrence after radical prostatectomy.

AB - Purpose: Biomarker signatures currently are used in several malignancies to guide clinical decision making. Recently, preoperative plasma levels of transforming growth factor-β1 (TGF-β1) and interleukin-6 soluble receptor (IL6-SR) have improved the accuracy of a clinical nomogram that predicted biochemical recurrence after radical prostatectomy. However, this model was never externally validated. We tested the accuracy of this nomogram in an independent, external cohort. Patients and Methods: Preoperative plasma levels of TGF-β1 and IL6-SR were measured in 423 consecutive men who underwent radical prostatectomy and bilateral lymphadenectomy and were used, along with preoperative prostate-specific antigen levels, biopsy Gleason sum, and clinical stage to determine nomogram-derived probabilities of biochemical recurrence-free survival at 5 years after radical prostatectomy. The accuracy of predictions was quantified with the area under the curve (AUC) and calibration plots that graphically displayed the nomogram's performance characteristics. The statistical significance of the difference between the biomarker nomogram and a model designed on the basis of clinical variables alone was tested by using the Mantel-Haenszel statistic. Results: Biochemical recurrence-free survival at 5 years was 77.0% (95% CI, 72.0% to 82.0%). The biomarker-based nomogram was 87.9% accurate versus 71.1% for the nomogram designed on the basis of clinical variables alone (16.8% difference; P <.001). The performance characteristics of the biomarker-based nomogram were superior to those of the clinical nomogram. Conclusion: We confirm that plasma levels of TGF-β1 and IL6-SR considerably enhance the accuracy of the standard preoperative nomogram for the prediction of biochemical recurrence after radical prostatectomy. This model further refines our ability to identify patients at a high risk of biochemical recurrence after radical prostatectomy.

UR - http://www.scopus.com/inward/record.url?scp=41149119907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149119907&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.4669

DO - 10.1200/JCO.2007.12.4669

M3 - Article

C2 - 18349404

AN - SCOPUS:41149119907

VL - 26

SP - 1526

EP - 1531

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -